A Phase 1 Clinical Trial of NXP900 in Subjects With Advanced Cancers
Phase 1
140
about 3.8 years
18+
10 sites in AZ, CO, FL +5
About this study
Researchers are testing a new treatment, NXP900, for advanced cancers. The trial will start with a small group of people to determine the best dose and then expand to more participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take NXP900
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of patients with treatment related adverse events and/or clinical laboratory abnormalities, Part A: Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol, Part B: Disease Control Rate (DCR), Part B: Duration of Response (DoR), Part B: Objective response rate (ORR)
Secondary: Apparent plasma clearance at steady state (Clss/F) of NXP900, Area under the concentration-time curve (AUC) of NXP900, Half-life (T1/2) of NXP900, Maximum observed concentration (Cmax) of NXP900, Time to peak concentration (Tmax) of NXP900
Oncology, Respiratory